Linsitinib ( DrugBank: Linsitinib )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 232 | Carney complex | 1 |
232. Carney complex
Clinical trial : 1 / Drugs : 3 - (DrugBank : 1) / Drug target gene : 1 - Drug target pathways : 29
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01560260 (ClinicalTrials.gov) | March 2012 | 20/3/2012 | Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors | A Phase 2 Study of Linsitinib (OSI-906) in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors | Carney Complex;Chondrosarcoma;Gastrointestinal Stromal Tumor;Paraganglioma | Other: Laboratory Biomarker Analysis;Drug: Linsitinib;Other: Pharmacological Study | National Cancer Institute (NCI) | NULL | Completed | 18 Years | N/A | All | 20 | Phase 2 | United States |